Trip of Compassion: A window into psychedelic-assisted therapies
Event description
Don’t miss out - Fundraiser Event - Adelaide's FIRST screening of the world acclaimed film - Trip of Compassion.
Our previous viewings have sold out within days of being announced. Get your tickets early!
Mind Medicine Australia is thrilled to welcome you to Adelaide's premiere screening of Trip of Compassion, an acclaimed Israeli documentary on MDMA-assisted psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). Trip of Compassion follows a number of patients participating in clinical trials in Israel, and is the first feature documentary to show footage from within psychedelic-assisted therapy sessions.
“I felt like I went through 15 years of psychological therapy in one night.”
– Patient featured in Trip of Compassion
You can watch the preview here:
Following the screening, there will be a Q & A panel. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.
"Trip of Compassion is the most compelling movie I've seen in the last year!"
– Tim Ferris, acclaimed author and podcaster
Director: Gil Karni,
Producers: Zafrir Kochanovsky & Miri Ezra - ttv Productions
Distributors: GO2FILMS
DATE: Wednesday 11th November 2020 - 7:00pm
Location: Eastend Palace Nova Cinemas, 3 Cinema Place, Adelaide
The theatre will open at 6:45pm for 7:00pm start – 9:30pm (incl Q&A Panel)
Ticket Price: $25 General Admission / $15 Concession
More about the panel
Dr Jörg Strobel
Dr. Jörg Strobel is a senior psychiatrist with the Barossa Hills Fleurieu local health network, and a senior lecturer at both Flinders and Adelaide universities. Dr. Strobel has a keen research interest in psychedelics.
Dr Shevaugn Johnson
Dr Shevaugn Johnson is originally from Canada, where she trained as a surgical and mental health nurse and obtained a bachelor’s degree in psychology with honours. Throughout the completion of her Doctorate in Clinical Psychology, Dr Johnson developed a special interest in the use of psychedelics to alleviate symptoms of mental health problems and has since published research papers on this topic. Dr Johnson is employed as a nurse and clinical psychologist at PsychMed and plans to work in the field of psychedelic psychotherapy, with the long-term goal of targeting populations with body image disturbance.
Dr Nick Ford
Dr Nick Ford is a psychiatrist in private practice with an interest in trauma, and a clinical lecturer at the University of Adelaide. He is also a reservist with the Royal Australian Army Medical Corps and has been awarded the Ciba Geigy Prize Psychiatry and Ames company Prize in Biochemistry. He has published numerous research works in the area of psychiatry and psychopharmacology.
Antanika Hoberg
Antanika Hoberg is the Australian Psychedelic Society chapter lead of Adelaide, editor of the APS national newsletter and a key part of the social media team. Antanika’s interest in the field began when she sought out psychedelics and MDMA as treatment for her treatment-resistant C-PTSD. she has since been passionately advocating for psychedelic medicines.
More about medicinal MDMA
Psychedelic-assisted therapies offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.
Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.
The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.
Many thanks to Mind Medicine Australia's Adelaide Chapter for faciliatating this event. Click here for more details about or to join the Adelaide Chapter.
Support psychedelic research and therapy development
By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.